Search

Your search keyword '"Sang-We, K."' showing total 1 results
Start Over Author "Sang-We, K." Topic disease progression
1 results on '"Sang-We, K."'

1. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722.

Author

Mok, T.S.K., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H.R., Wu, Y-L., Gainor, J., Lee, S-H., Chiu, C-H., Sang-We, K., Cheng-Ta, Y., Liang, W., Wu, L., Lin, M-C., Samol, J., Zhang, X., Sylvester, J., Li, S., and Yang, J.C-H.

Subjects
*NON-small-cell lung carcinoma, *PROTEIN-tyrosine kinase inhibitors, *NIVOLUMAB, *DISEASE progression, *EPIDERMAL growth factor receptors
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results